Participants and Sample Collection
Informed consent was obtained prior to study initiation. This study was
approved by the institutional review board at Cedars-Sinai Medical
Center (protocol IRB numbers: 000 42267 and 000 00621). The study was
conducted in accordance with the ethical guideline based on federal
regulations and the common rule. The study was composed and written
entirely by the authors who vouch for the results presented here.
Nineteen healthy controls, 134 patients with confirmed COVID-19
infection (of which, 14 received vaccination), and 38 vaccinated healthy
individuals without history of SARS-CoV-2 infection were enrolled in the
study with similar age and gender composition. The demographics of 134
patients are shown in Table 1. The time of blood draw from previously
infected patients ranged from day 16 to day 388 (Median = 102) after
reported SARS-CoV-2 infection by viral PCR and/or antibody test. The
blood from vaccinated individuals was drawn 1-month post
2nd dose of Pfizer BNT162b2 mRNA vaccine. Fresh whole
blood was collected in sodium heparinized tubes and stimulated with
SARS-CoV-2 peptides overnight. Plasma obtained was stored at -80°C for
SARS-CoV-2 Spike IgG analysis.